IVA
Price
$3.68Alerts
Change
-$0.20 (-5.15%)
Updated
Nov 13 closing price
Capitalization
897.69M
7 days until earnings call
Intraday BUY SELL Signals
SLDB
Price
$6.84Alerts
Change
-$0.16 (-2.29%)
Updated
Nov 13 closing price
Capitalization
706.61M
120 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IVA vs SLDB

IVA vs SLDB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IVA vs. SLDB commentary
Nov 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IVA is a StrongBuy and SLDB is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IVA with price predictions
Nov 13, 2026

IVA's RSI Indicator leaves overbought zone

The 10-day RSI Oscillator for IVA moved out of overbought territory on November 04, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 20 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 53 cases where IVA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on IVA as a result. In 79 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for IVA just turned positive on October 20, 2026. Looking at past instances where IVA's MACD turned positive, the stock continued to rise in 28 of 38 cases over the following month. The odds of a continued upward trend are 74%.

IVA moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IVA crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.

Following a +4.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVA advanced for three days, in 175 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

IVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 115 of 158 cases where IVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. IVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.215) is normal, around the industry mean (3.498). P/E Ratio (-7.170) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (136.986) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for SLDB with price predictions
Nov 13, 2026

SLDB saw its Stochastic Oscillator recovers from the overbought zone

The Stochastic Oscillator for SLDB moved out of overbought territory on November 13, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 46 similar instances where the indicator exited the overbought zone. In 44 of the 46 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

SLDB moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for SLDB moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLDB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

SLDB broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SLDB's RSI Oscillator exited the oversold zone, 34 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on SLDB as a result. In 60 of 69 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

The Moving Average Convergence Divergence (MACD) for SLDB just turned positive on October 21, 2026. Looking at past instances where SLDB's MACD turned positive, the stock continued to rise in 30 of 42 cases over the following month. The odds of a continued upward trend are 71%.

Following a +8.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLDB advanced for three days, in 200 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

The Aroon Indicator entered an Uptrend today. In 142 of 171 cases where SLDB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.889) is normal, around the industry mean (3.498). P/E Ratio (-3.487) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. SLDB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLDB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
IVA vs SLDB: Fundamental Ratings
IVA
SLDB
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
30
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
5242
P/E GROWTH RATING
1..100
2720
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (30) in the Biotechnology industry is significantly better than the same rating for IVA (99) in the null industry. This means that SLDB’s stock grew significantly faster than IVA’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IVA (100) in the null industry. This means that SLDB’s stock grew similarly to IVA’s over the last 12 months.

SLDB's SMR Rating (98) in the Biotechnology industry is in the same range as IVA (100) in the null industry. This means that SLDB’s stock grew similarly to IVA’s over the last 12 months.

SLDB's Price Growth Rating (42) in the Biotechnology industry is in the same range as IVA (52) in the null industry. This means that SLDB’s stock grew similarly to IVA’s over the last 12 months.

SLDB's P/E Growth Rating (20) in the Biotechnology industry is in the same range as IVA (27) in the null industry. This means that SLDB’s stock grew similarly to IVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IVASLDB
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
87%
MACD
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
75%
Bullish Trend 5 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
83%
COMPARISON
Comparison
Nov 16, 2026
Stock price -- (IVA: $3.68 vs. SLDB: $6.84)
Brand notoriety: IVA and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IVA: 112% vs. SLDB: 58%
Market capitalization -- IVA: $897.69M vs. SLDB: $706.61M
IVA [@Biotechnology] is valued at $897.69M. SLDB’s [@Biotechnology] market capitalization is $706.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IVA’s FA Score shows that 1 FA rating(s) are green while SLDB’s FA Score has 2 green FA rating(s).

  • IVA’s FA Score: 1 green, 4 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than IVA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IVA’s TA Score shows that 7 TA indicator(s) are bullish while SLDB’s TA Score has 5 bullish TA indicator(s).

  • IVA’s TA Score: 7 bullish, 3 bearish.
  • SLDB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, IVA is a better buy in the short-term than SLDB.

Price Growth

IVA (@Biotechnology) experienced а -3.16% price change this week, while SLDB (@Biotechnology) price change was +3.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.

Reported Earning Dates

IVA is expected to report earnings on Nov 23, 2026.

SLDB is expected to report earnings on Mar 16, 2027.

Industries' Descriptions

@Biotechnology (-3.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

IVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IVA has been loosely correlated with SLDB. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if IVA jumps, then SLDB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IVA
1D Price
Change %
IVA100%
-5.15%
SLDB - IVA
41%
Loosely correlated
-2.29%
IMNM - IVA
39%
Loosely correlated
+0.37%
MGTX - IVA
38%
Loosely correlated
+4.44%
DNTH - IVA
38%
Loosely correlated
-0.72%
PTGX - IVA
38%
Loosely correlated
-2.55%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WY20.810.35
+1.71%
Weyerhaeuser Company
BWFG72.340.83
+1.16%
Bankwell Financial Group
FNWB9.78-0.06
-0.61%
First Northwest Bancorp
DAC150.12-1.67
-1.10%
Danaos Corp
NWTG0.93-0.04
-3.87%
Newton Golf Company Inc